- Home
- SUZ vs PCVX Comparison
SUZ vs PCVX Comparison
Compare SUZ & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUZ
- PCVX
- Stock Information
- Founded
- SUZ 1924
- PCVX 2013
- Country
- SUZ Brazil
- PCVX United States
- Employees
- SUZ N/A
- PCVX N/A
- Industry
- SUZ Paper
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- SUZ Basic Materials
- PCVX Health Care
- Exchange
- SUZ Nasdaq
- PCVX Nasdaq
- Market Cap
- SUZ 11.6B
- PCVX 4.4B
- IPO Year
- SUZ N/A
- PCVX 2020
- Fundamental
- Price
- SUZ $9.29
- PCVX $33.10
- Analyst Decision
- SUZ
- PCVX Strong Buy
- Analyst Count
- SUZ 0
- PCVX 10
- Target Price
- SUZ N/A
- PCVX $136.50
- AVG Volume (30 Days)
- SUZ 1.9M
- PCVX 1.5M
- Earning Date
- SUZ 08-07-2025
- PCVX 08-05-2025
- Dividend Yield
- SUZ 2.85%
- PCVX N/A
- EPS Growth
- SUZ N/A
- PCVX N/A
- EPS
- SUZ N/A
- PCVX N/A
- Revenue
- SUZ $8,633,051,515.00
- PCVX N/A
- Revenue This Year
- SUZ $17.17
- PCVX N/A
- Revenue Next Year
- SUZ $9.27
- PCVX N/A
- P/E Ratio
- SUZ N/A
- PCVX N/A
- Revenue Growth
- SUZ 30.47
- PCVX N/A
- 52 Week Low
- SUZ $8.41
- PCVX $27.66
- 52 Week High
- SUZ $10.98
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- SUZ 47.80
- PCVX 42.61
- Support Level
- SUZ $9.24
- PCVX $32.06
- Resistance Level
- SUZ $9.44
- PCVX $33.81
- Average True Range (ATR)
- SUZ 0.16
- PCVX 1.23
- MACD
- SUZ -0.03
- PCVX -0.16
- Stochastic Oscillator
- SUZ 11.59
- PCVX 8.44
About SUZ Suzano S.A.
Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.